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Branched-chain 2-methyl fatty acids are derived from abundant dietary lipids and cholesterol. β-
Oxidation of these lipids requires S stereochemistry, but those with R stereochemistry are common. α-
Methylacyl-CoA racemase (AMACR; P504S) catalyses chiral inversion, enabling subsequent 
metabolism. The enzyme is also important for conversion of the R- enantiomers of ibuprofen and related 
drugs to their pharmacologically active S- enantiomers. The enzyme works by a 
deprotonation/reprotonation mechanism via an enolate intermediate.1 
 
AMACR protein levels and activity are increased in all prostate cancers. Reduction of AMACR levels 
using siRNA causes prostate cancer cells to revert to a more normal phenotype, including restoration of 
androgen dependent growth. The enzyme is therefore a promising new drug target. However, 
development of this target has been hampered by the difficulties in measuring chiral inversion and the 
resulting lack of a convenient, high-throughput assay. Consequently, only three studies on inhibitors of 
AMACR have been reported since 2001. 
 
Incubation of novel substrates containing fluorine with active human recombinant AMACR 1A resulted 
in the formation of an unsaturated product. Negative controls containing inactive enzyme did not produce 
a significant level of unsaturated product. Incubation of the unsaturated product and fluoride with active 
enzyme did not result in the formation of substrate, showing that the elimination reaction was irreversible. 
Steady-state kinetic analysis of the reaction shows that the elimination of fluoride from this substrate is 
ca. 32 x more efficient than chiral inversion of S-2-methyldecanoyl-CoA, as judged by kcat/Km. This new 
reaction has the potential to lead to the development of a high-throughput assay for discovery of AMACR 
inhibitors and may also aid the development of more convenient techniques for diagnosing and 
monitoring prostate cancer.  
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